FILTER
FILTERED INTERVIEW RESULTS
Rodrigo Couto
PRESIDENT – LATIN AMERICA, HEXAGON’S MINING DIVISION
Hexagon offers clients an integrated ecosystem that guarantees a single source of data, which is automatically transformed into actionable information, connecting different workflows to enhance efficiency and productivity.
Esteban Hormazabal
MANAGING DIRECTOR – CHILE, SRK CONSULTING
SRK Consulting in Chile speaks of mine closure and how environmental regulations will impact its business.
Joshua Olmsted
PRESIDENT AND COO – AMERICAS, FREEPORT-MCMORAN
Freeport-McMoral updates GBR on its strategy for Chile.
Christian Cavagnaro
MANAGING DIRECTOR, TAKRAF CHILE
TAKRAF gives examples of how its material handling solutions benefit mines.
Iván Arriagada
CEO, ANTOFAGASTA PLC
Iván Arriagada provides an update on Antofagasta Minerals’ Chilean operations.
Don Lindsay
PRESIDENT & CEO, TECK RESOURCES LIMITED
Don Lindsay details the development of Teck’s QB2 project in Chile.
Joshua Olmsted
PRESIDENT AND COO – AMERICAS, FREEPORT-MCMORAN
Joshua Olmsted outlines Freeport McMoRan’s growth strategy in the Americas.
Aurora Davidson
PRESIDENT & CEO, AMERIGO RESOURCES
Aurora Davidson explains Amerigo Resources’ business model and evolution of the MVC operation.
Raymond Jannas & Craig Nelsen
PRESIDENT AND CEO & CHAIRMAN, ATEX RESOURCES
ATEX Resources discusses copper porphyry exploration at its Valeriano project.
Shawn Wallace
EXECUTIVE CHAIR, TORQ RESOURCES
Torq Resources describes the potential it sees in its Santa Cecilia project.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
